Mammography in India: Prep, Procedure, BI-RADS & Costs

• Mammography is a low-dose X-ray that can detect breast changes before they can be felt; in India, average-risk screening commonly begins at 40 and continues to about 69, every one to two years.
• Schedule the test 7–10 days after your period starts and skip deodorant, talc, lotion, or perfume on the chest and underarms that day, as these can mimic calcifications.
• Compression is brief (about 5–10 seconds per image) and the full exam usually takes 10–15 minutes; discomfort is normal, but real pain should be flagged to the technician.
• Your report uses BI-RADS categories 0–6; focus on the recommendation line, not just the number. BI-RADS 1–2 are normal/benign, 3 needs short follow-up, 4–5 usually need a biopsy.
• Dense breasts, common in Indian women, lower mammography's sensitivity, so ultrasound is often added; a normal mammogram never overrules a persistent lump.
• A private screening mammogram costs roughly Rs 1,500–4,500; public hospitals and Ayushman Bharat pathways can make it free or low-cost.

Mammography is a low-dose X-ray of the breast designed to find changes that touch and symptoms can miss. It is the main imaging test used for breast cancer screening in women over 40, and an important diagnostic test when there is a new symptom such as a lump, skin thickening, focal one-sided pain, nipple inversion, or bloody nipple discharge. In India, digital mammography is now standard in most organised breast clinics and radiology departments, from Tata Memorial Hospital and Rajiv Gandhi Cancer Institute to Apollo, Fortis, and Manipal, as well as many mid-sized city centres. The aim is not just to "find cancer" but to sort normal tissue from probably benign change, suspicious findings, and abnormalities that need closer comparison with earlier films.

The standard form today is 2D digital mammography (DM), the workhorse most women receive for screening. A newer approach, digital breast tomosynthesis (DBT) or 3D mammography, takes multiple low-dose images from different angles and reconstructs thin slices, which reduces the problem of normal tissue overlapping on a flat 2D image. That is especially useful in dense breasts, which are common in premenopausal Indian women. Even so, a good-quality 2D study read carefully by a trained breast radiologist is far more useful than delaying screening while waiting for a "perfect" machine.

What mammography can detect is broader than many women realise. It can show a distinct mass, but also microcalcifications (tiny calcium specks that sometimes cluster in patterns linked to ductal carcinoma in situ or early invasive cancer), asymmetry (one area looking different from the matching spot on the other side), and architectural distortion (the normal pattern looking pulled or disrupted before a clear lump forms). It also confirms many benign findings, such as coarse calcifications, cyst patterns, Fibroadenoma of the Breast in India: Symptoms, Diagnosis & Cost features, and post-surgical change. That is why a mammogram is not a simple yes-or-no cancer test; it is a structured imaging language that guides whether more views, ultrasound, or biopsy are needed. If you are checking a symptom rather than attending routine screening, related reading includes breast lump red flags and causes of nipple discharge.

It also helps to separate screening from diagnostic mammography. A screening mammogram is done in a woman with no current symptoms and usually includes four standard images, two views of each breast. A diagnostic mammogram is more targeted, used when there is a symptom, a prior abnormal screen, or a need to zoom in with extra compression, magnified views, or same-day ultrasound. The distinction matters in India, where many women first meet mammography only after they are worried, whereas Indian Cancer Society camps and Pinkathon-linked awareness drives are trying to normalise testing before symptoms appear. The test works best when seen as a preventive imaging tool, not a last resort after months of delay.

Screening recommendations differ between countries because they depend on local disease patterns, resources, and age structure. In India, the practical message from many breast specialists is that average-risk women aged 40 to 69 should discuss regular mammography, usually every one to two years, rather than waiting until 50 as some older Western models suggested. This is not arbitrary: ICMR-National Cancer Registry data and multiple Indian hospital series show breast cancer presenting at a younger median age here, around 50, versus roughly 62 in US registries. A blanket "start at 50" rule risks missing cancers in Indian women in their 40s, particularly in cities where later childbirth, shorter breastfeeding, obesity, and sedentary work have shifted risk.

Age is not the only variable. A healthy, symptom-free 43-year-old in Pune may still benefit from a baseline screen. A 52-year-old in Madurai who has never been screened has not "missed the window"; starting now is still worthwhile. A fit 67-year-old with reasonable life expectancy can continue every one to two years. Screening is less about a birthday trigger and more about building a steady habit during the years when the benefit is highest.

High-risk women follow a different path. Those with BRCA1 or BRCA2 mutations, very strong family histories, prior chest radiation at a young age, or certain high-risk biopsy results need earlier, more intensive surveillance. In India, many specialists advise MRI-based surveillance from around 25 to 30 for BRCA carriers, with mammography added from about 30. Some women with a mother or sister diagnosed young are told to begin roughly ten years before the youngest family diagnosis (but not before the mid-20s) and to combine MRI and mammography. That is why family history is not a casual OPD detail: "my mother had breast cancer at 42 and my aunt had ovarian cancer" is a genetics conversation. See our guides to BRCA testing in India and ovarian cancer warning signs.

Indian family realities shape when women actually show up. Some need a spouse's or in-laws' agreement to spend on a test, some are caring for children or elders, and some in rural districts have no mammography unit nearby. That is why opportunistic screening matters: a visit to Apollo, Fortis, Manipal, HCG, or a district cancer centre for something else can be the moment to raise it, and at public health and wellness centres a clinical breast exam can be the entry point to referral. The bottom line: for average-risk Indian women, screening commonly begins at 40 and continues to about 69 every one to two years; high-risk women often start much earlier and use MRI heavily. The exact interval should still be individualised with a clinician, especially if prior films show dense tissue or new family history emerges.

Preparation is simple, but small details make the experience smoother and the images more reliable. If you still have periods, try to book the exam about 7 to 10 days after your period starts, when breasts are often less swollen and less tender, which makes compression easier to tolerate. Ignoring this timing is not dangerous, just potentially more uncomfortable. At popular Indian centres where slots fill fast, plan ahead rather than taking the first available appointment. For postmenopausal women, cycle timing does not matter, so the focus shifts to convenience, transport, and carrying prior reports.

On the day, do not apply deodorant, talcum powder, body lotion, perfume spray, or glitter products on the breasts, chest wall, or underarms. This sounds fussy but is technically important: tiny particles can show up as white specks that mimic calcifications, causing confusion or an unnecessary recall. It is especially relevant in India, where talc is used routinely (Nycil, Ponds Dreamflower, prickly-heat powders in hot months), and even underarm creams or lotions can interfere. A bath is fine; just keep the chest and underarm skin clean and dry, with nothing applied, until after the exam.

Clothing and paperwork matter more than people expect. A two-piece outfit, such as a kurta and palazzo, salwar kameez, jeans and top, or saree with blouse, is easier than a one-piece dress because you only undress from the waist up. Skip heavy necklaces. Bring prior mammograms, ultrasounds, biopsy reports, discharge summaries, and any CDs or films. Comparison with earlier studies is one of a radiologist's most powerful tools: a stable benign asymmetry seen unchanged over three years is managed very differently from a new one. Women often say "the old films are at my mother's house," but those images can prevent extra anxiety and extra tests.

Mental preparation is the last piece. Many women arrive with second-hand fear from relatives, WhatsApp forwards, or a dramatic account of "how much it hurt." It helps to know the compression lasts only a few seconds at a time and that the staff do this all day with women of every age. If you are anxious, tell the technician before you start. Some women take paracetamol 500 mg about 30 to 60 minutes beforehand if they are prone to tenderness; it is optional but can help. If you are pregnant, possibly pregnant, breastfeeding, or have breast implants, tell the centre in advance so the plan can be adjusted or ultrasound prioritised. Mention limited mobility, a recent shoulder injury, or severe anxiety before positioning, as small changes in pace and arm support make the test easier. If you have had prior breast surgery, keep the operative note or a simple written list of past procedures handy, as it helps the radiologist interpret expected post-treatment changes.

A mammogram is a short outpatient test, but the unfamiliar machine can make it feel more intimidating than it is. After registration you will usually undress from the waist up and wear a front-opening gown. A female radiographer or mammography technician performs the imaging in most Indian centres, which matters to many women for comfort. The technician confirms your name, age, any symptoms, date of last period if relevant, past surgery, and whether you have implants. For a diagnostic study, the radiologist may review your complaint first. You stand facing the machine, and one breast at a time is placed on a flat detector plate.

The breast is gently pulled forward so as much tissue as possible is included, then a clear plastic paddle lowers and presses it firmly against the plate. Compression is not meant to be harsh; it is necessary for image quality. It spreads the tissue, reduces blur from movement, lowers the radiation dose, and makes small findings visible. You will be asked to stay still and sometimes hold your breath for a few seconds. The first common view is the craniocaudal (CC) view, looking from above down onto the breast. The machine is then repositioned for the mediolateral oblique (MLO) view, an angled image that includes the upper outer breast and the armpit tail where cancers can appear. The same sequence repeats on the other side.

A routine screening exam usually takes four standard views: CC and MLO of the right breast, and CC and MLO of the left. If there is a diagnostic question, extra views may be added, such as spot compression, magnification views for calcifications, true lateral views, or implant-displaced views. Centres using 3D tomosynthesis acquire the images slightly differently, but the experience is similar. Each image's compression generally lasts about 5 to 10 seconds. The full appointment, including positioning and dressing, often takes 10 to 15 minutes for screening, and somewhat longer if extra images or same-day ultrasound are needed.

After the images are taken, some centres let you leave and send the report later, while others review the images on the spot and may call you back for additional views before you go. A request for more views does not automatically mean something serious; often the tissue simply overlapped in one view and needs a second look. In many Indian workflows, a mammogram and targeted ultrasound are done the same day if there is a symptom or dense tissue. That combined approach saves repeated travel, which matters for women coming from another town or juggling work and family. Most women come out saying the exam was awkward and briefly uncomfortable, but much quicker and more manageable than the fear they carried in.

The honest answer about mammography pain is that it is usually uncomfortable rather than truly painful, and the discomfort is brief. Compression can feel tight, pressing, pinching, or briefly sharp, especially with tender premenstrual breasts, very small breasts, surgical scars, or anxiety that causes muscle tensing. But the intensity is concentrated into a few seconds per image, not the whole appointment. Many women who delayed the test for years later say the anticipation was worse than the imaging. Others do find it painful, and that should not be dismissed; pain tolerance and breast characteristics vary. The fair message is that discomfort is expected, temporary, and purposeful, not a sign that something is wrong. If you have ongoing cycle-related breast pain, mention it so positioning can be paced.

Compression works by spreading the tissue into a thinner layer so small abnormalities are less likely to hide. If the breast is under-compressed, the image can blur, tissue overlaps, and a subtle lesion may be missed or an unnecessary callback generated. Understanding this often helps women reinterpret the sensation: it is not the machine "crushing" the breast, it is the shortest route to a readable image. A skilled technician uses the minimum compression that still gives diagnostic quality, and you can ask to pause if the pain is too much. Good communication matters more than silently enduring fear.

For women likely to be more uncomfortable, there are simple steps. Scheduling 7 to 10 days after the period starts helps most. Wearing a supportive bra afterward can ease mild soreness for a few hours. Paracetamol 500 mg before the appointment is reasonable for those very anxious about pain or with significant prior tenderness; ibuprofen may also help, but paracetamol is often the simpler choice unless a doctor advises otherwise. Deep breathing, dropping the shoulders, and resisting the instinct to pull away during compression all help, since tensed muscles make positioning harder.

Afterward, most women feel normal right away or have only minor soreness. Mild bruising is uncommon but can happen, especially on blood thinners, with fragile skin, or after a very firm compression. Severe pain afterward is unusual and should prompt a call to the centre. Women with prior lumpectomy scars, chest-wall tenderness, or implant tightness should mention it during positioning, as technique can be adapted. If fear of pain has kept you away for years, book at a dedicated breast unit rather than a rushed general slot, where pacing and explanation change the experience. Being accompanied by a calm sister, friend, or partner helps too. The key message for women hearing family gossip or frightening social media stories: a mammogram is not meant to be a traumatic ordeal. It is a short test with brief compression, usually manageable, and worth tolerating because it can find disease earlier, when treatment is simpler and outcomes are better.

Most reports use the BI-RADS system, short for Breast Imaging Reporting and Data System, a standardised language that turns an image interpretation into a management plan. Many women look only at "normal" or "abnormal," but the BI-RADS category is more useful because it tells you the level of concern and what should happen next. Whether your report comes from a large cancer centre, a private breast clinic, or a city diagnostic chain, BI-RADS reduces vague wording and improves communication between the radiologist, breast surgeon, oncologist, and you. Learning the categories prevents unnecessary panic, because not every abnormality means cancer and not every callback means biopsy.

BI-RADS 0 means the study is incomplete; it does not mean cancer. The radiologist needs more imaging or old films for comparison before assigning a final category, often when a screening mammogram shows an asymmetry that may just be overlapping tissue. BI-RADS 1 means negative, with no significant abnormality. BI-RADS 2 means benign, such as clearly benign calcifications, a known intramammary lymph node, or a stable post-surgical change. Both 1 and 2 return to routine screening. BI-RADS 3 means probably benign, with a very low chance of cancer (usually under 2 percent), and the recommended action is short-interval follow-up, commonly repeat imaging in six months rather than immediate biopsy.

BI-RADS 4 and 5 usually trigger a tissue diagnosis. BI-RADS 4 means a suspicious abnormality and biopsy should be considered; it is a broad category sometimes split into 4A, 4B, and 4C to reflect rising likelihood of cancer, but the practical message is the same, imaging alone is not enough and a core needle biopsy is usually next. BI-RADS 5 means highly suggestive of malignancy, where the pattern is strongly concerning and prompt action is needed. BI-RADS 6 is used when cancer is already proven on biopsy and imaging is being used for staging or follow-up. Women often ask whether BI-RADS 5 means there is no hope; it does not. It means the lesion looks malignant on imaging, but the outcome depends on stage, biology, and access to care, not the label.

The safest way to read a report is to focus on the recommendation line as much as the category. If it says BI-RADS 0, find out what extra imaging is needed. If BI-RADS 3, mark the six-month follow-up date rather than disappearing out of relief. If BI-RADS 4 or 5, move quickly toward a breast clinic or breast surgeon rather than spending weeks collecting opinions without a tissue diagnosis. In India, women sometimes carry reports from centre to centre while family members debate; that delay can harm more than the result itself. Ask for the actual images or CD if you may need a second opinion. If words like calcifications, asymmetry, or architectural distortion are unfamiliar, ask exactly which feature triggered the category, and write down the advised next step before leaving. BI-RADS exists precisely so women and clinicians can move from vague fear to a defined next action.

Breast density is one of mammography's most important limitations, and it is especially relevant in India because a large share of premenopausal women have dense breasts. Dense breasts contain more fibroglandular tissue and less fat. On a mammogram, both dense tissue and many cancers appear white, so an abnormality can blend into the background like a white cloud against a white sky, while fatty tissue appears darker and makes lesions easier to see. That is why mammography is often more sensitive in older postmenopausal women and less sensitive in younger, denser breasts. Indian radiology and hospital series suggest dense breasts are common in roughly 60 to 80 percent of premenopausal Indian women, so this is not a niche issue.

Density matters in two ways. First, it lowers mammographic sensitivity, so the test can miss cancers that would be obvious in a fatty breast. Second, higher density is itself linked to a somewhat increased breast cancer risk. This does not make dense breasts abnormal or dangerous, many healthy women have them, but it does mean a "normal mammogram" in a very dense breast sometimes needs added context. If a woman has a persistent palpable lump but a mammogram that is hard to read because of density, the workup is not over. That is one reason ultrasound is so often paired with mammography in India, particularly in symptomatic and younger women.

Supplemental ultrasound can find lesions hidden in dense tissue, especially solid masses or cysts that match a palpable area. It does not replace mammography, since it is less reliable for certain calcification patterns, but it is an important complement; our guide to how breast and pelvic ultrasound is done in India explains the broader role of ultrasound. Tomosynthesis can also improve detection in dense breasts by reducing tissue overlap, which is why some Apollo, Fortis, Manipal, and specialist centres increasingly recommend DBT for heterogeneously or extremely dense tissue. In selected high-risk women, MRI is the most sensitive supplemental test, though cost and access are major constraints. Many women hear "dense breasts" and think it is a diagnosis; it is better understood as a tissue characteristic that changes how confidently imaging can see through the breast.

The practical lesson is that dense breasts should make you more organised, not more alarmed. Ask whether the density category changes the screening plan and whether same-day ultrasound is useful. Keep prior studies carefully, because stability over time is especially helpful in dense tissue. If you have symptoms despite a reassuring mammogram, say so clearly and insist on symptom correlation rather than accepting a generic report. Dense breasts are not the same as large, painful, or "bad" breasts; they are simply a radiologic pattern. The same woman can become less dense after menopause, which changes how later mammograms read. For many Indian women in their 40s, the best pathway is not mammography alone but mammography plus ultrasound, with tomosynthesis or MRI added selectively depending on density, family history, and cost. The point is not that mammography "doesn't work" in dense breasts; it is that dense breasts need a more layered strategy and a careful reading of what a negative test does and does not rule out.

An abnormal mammogram is stressful, but it is not the same as a cancer diagnosis. The first step is to identify what kind of abnormality was seen and whether the next move is more imaging or a biopsy. Many callbacks after screening are simply for extra views or ultrasound, often for overlapping tissue, a partly seen asymmetry, or calcifications that need magnification, and many end in a benign conclusion. When the report reaches BI-RADS 4 or 5, the usual next step is tissue sampling rather than more waiting. In India, the preferred method for most suspicious findings is core needle biopsy, often ultrasound-guided if the lesion is visible on ultrasound, or stereotactic-guided for mammographic calcifications or distortion.

Core needle biopsy is preferred over FNAC in most modern breast units because it provides more tissue, preserves architecture, and supports receptor testing if cancer is found. FNAC still has a role, such as a clearly suspicious lymph node or a superficial lesion, but it is generally less informative for a definitive breast diagnosis. During a core biopsy, local anaesthesia is used, a small needle device takes tissue samples, and it is usually a day-care visit, not major surgery. Results commonly take about 5 to 7 days in private centres and a little longer in busy government hospitals. That wait is emotionally hard, but a week to a real answer is far better than a month of repeated opinions without a tissue diagnosis.

Once pathology is available, care should ideally move into a multidisciplinary breast clinic rather than scattered consultations, coordinating radiology, pathology, breast surgery, medical oncology, and sometimes radiation oncology. Large Indian centres such as Tata Memorial, RGCI, Apollo, Fortis, HCG, and Manipal increasingly work this way. If the biopsy is benign and matches the imaging, the plan may be observation or simple excision. If cancer is diagnosed, the next steps usually include receptor testing, imaging for the extent of disease, and a plan that may start with surgery or with chemotherapy before surgery depending on tumour size, nodal status, and subtype; our overview of breast cancer detection and treatment in India walks through what follows. For younger women, asking early about fertility preservation before cancer treatment can matter.

Logistics matter almost as much as medicine. Ask for copies of images and pathology. Clarify whether the lesion seen on mammography was definitely sampled. Bring a family member for support, but avoid turning each step into a family referendum that delays action. If cost is a concern, ask immediately about Ayushman Bharat eligibility, state insurance schemes, hospital social workers, or public-sector transfer options rather than waiting until after the diagnosis is set. If the first centre cannot coordinate imaging, biopsy, and surgery efficiently, shifting early to a dedicated breast clinic can save weeks. Ask who will communicate the result and whether a breast-surgeon appointment should be booked in advance. If the biopsy is for calcifications, ask whether a post-biopsy clip or check mammogram will document the sampled site. Keep the biopsy date, result date, and follow-up appointment written in one place. The useful frame: an abnormal mammogram means the breast needs clarification, and the faster you move from uncertain imaging to a precise diagnosis, the faster the situation becomes treatable, whether the finding turns out benign or malignant.

Cost is one of the biggest reasons Indian women postpone mammography, but the reality is more varied and often more manageable than expected. In the private sector, a standard screening mammogram commonly costs about Rs 1,500 to Rs 4,500 depending on city, brand, and whether a radiologist consultation is bundled. Digital breast tomosynthesis is usually higher, often around Rs 3,500 to Rs 8,000. Metro hospitals and premium women's health packages may charge more, independent diagnostic centres often less. The test is not free in most private settings, but it is also not a rare luxury procedure; for many middle-class families the cost is comparable to a few routine household expenses that rarely get the same scrutiny.

Access is better in cities but still unequal. Women in Delhi, Mumbai, Bengaluru, Chennai, Hyderabad, Kolkata, Pune, Kochi, and Ahmedabad can usually choose among Tata Memorial-linked units, RGCI, Apollo, Fortis, Manipal, HCG, and established diagnostic chains. In tier-2 cities, access may hinge on one or two hospitals or a visiting radiology schedule. In rural districts, the biggest barrier is often not price but physical availability, travel distance, and the need to take a full day away from work or family. Mobile mammography vans partly address this gap; Indian Cancer Society community programmes and some state screening initiatives use them to reach workplaces and underserved areas, though coverage is uneven.

Government and subsidised pathways deserve more attention. At tertiary public hospitals such as AIIMS, the Tata Memorial network, regional cancer centres, and some teaching hospitals, mammography may be free or available at nominal cost. Ayushman Bharat PM-JAY can cover diagnostic pathways and treatment for eligible families, though the practical experience depends on empanelment and documentation. Some state schemes and district programmes support diagnostic referral after an abnormal clinical breast examination. The challenge is that screening infrastructure is still not uniformly built into every district facility, so many women enter the system only after a symptom appears, which is why public-health efforts keep focusing on clinical breast examination and referral networks.

Access is also shaped by household economics. Women may spend on children's tuition, parents' medicines, or festival purchases before an asymptomatic test for themselves, and some are told "why do this if nothing is wrong?" Others fear that if the test shows something, treatment costs will be unmanageable. Those worries are not irrational, but they should be met with planning rather than avoidance. Ask the centre for a transparent estimate, check insurance wellness benefits, and ask whether screening camps are running. If a private mammogram is unaffordable, ask for a referral to a public breast clinic instead of abandoning screening. A socially supported mammogram is often more feasible than an isolated one, which is why women do better when a sister, friend, or neighbour goes along. Ask whether one trip can include clinical examination, mammography, and ultrasound to cut repeat travel, and whether the centre offers women's health package days or lower-priced weekday slots. In India, the question is often not whether mammography exists, but whether a woman gets enough logistical, financial, and family support to reach it in time and return for follow-up.

Mammography is valuable but not perfect, and women deserve an honest account of its limits. Overall sensitivity is often described as around 75 to 85 percent, but that number shifts with age, breast density, lesion type, and whether the test is screening or diagnostic. Sensitivity tends to be lower in dense breasts and younger women and higher in fattier postmenopausal breasts. Some cancers are simply not obvious on mammography, especially if they do not calcify or if they hide in dense glandular tissue. This is why a "normal mammogram" should never automatically overrule a persistent clinical concern: if a doctor can clearly feel a suspicious lump, further workup still matters even if the mammogram looks unremarkable. The test is strong, but it is not infallible.

Ultrasound is the most common complementary test in Indian practice, especially useful in women under 40, in dense breasts, and for evaluating a palpable lump, focal pain, or a mammographic area needing correlation. It distinguishes cystic from solid lesions well and is widely available even where mammography is inconsistent. But ultrasound is operator-dependent, less standardised as a population screening tool, and not as good as mammography for suspicious microcalcifications, so it is best seen as complementary, not competitive. In practice, the mammogram-plus-ultrasound combination is often what gives the clearest answer for women in their 40s and 50s, particularly with dense tissue or symptoms.

MRI has the highest sensitivity of the major breast imaging tools and is especially important for women at high inherited risk, such as BRCA carriers, and for problem-solving when mammography and ultrasound are inconclusive. It can find cancers others miss, but it is expensive, less widely available, and more likely to produce findings that need follow-up, which makes it unsuitable as a universal screening test for average-risk women. Clinical breast examination and breast self-awareness still matter too. They are not substitutes for mammography, but they help women notice changes between screening rounds and may be the first detection route where imaging access is limited; see our calm, practical guide to the monthly breast self-exam. If you want a symptom-oriented framework rather than a screening one, read when a breast lump is worth worrying about and the guide to focal, non-cyclic breast pain.

The balanced conclusion is that mammography works best as part of a layered strategy. Average-risk women aged 40 to 69 usually need periodic mammography. Women with dense breasts may need supplemental ultrasound or tomosynthesis. High-risk women may need MRI from a younger age. All women benefit from knowing what their breasts normally feel like, seeking evaluation for new changes, and not assuming one normal image closes the case forever, a point that is especially important after a reassuring report in a dense breast or in a woman with persistent symptoms. None of these alternatives cancels the value of mammography; they work best filling the gaps it leaves. A thoughtful clinician uses the strengths of each tool rather than pretending one test answers every breast concern, and a thoughtful patient remembers that a normal test today does not remove the need for future screening or new-symptom review.

Most callbacks and abnormal findings end in reassurance, but a few changes deserve a prompt, organised response rather than "let us wait and see." Use this list to decide when to act quickly.

• World Health Organization — Breast cancer fact sheet
• WHO — Breast cancer screening (Guide & position)
• American College of Radiology — ACR BI-RADS Atlas
• ICMR–NCDIR National Cancer Registry Programme
• Tata Memorial Centre — Department of Radiodiagnosis (breast imaging)
• National Health Authority — Ayushman Bharat PM-JAY